Champions Oncology (CSBR) EPS (Diluted) Growth (1y) (2014 - 2026)
Champions Oncology (CSBR) EPS (Diluted) Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 96.09% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 144.25% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 315.14% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -11.18% |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | 62.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 62.51% |
| Jan 31, 2026 | -106.42% |
| Oct 31, 2025 | -68.44% |
| Jul 31, 2025 | -136.14% |
| Apr 30, 2025 | -1,498.62% |
| Jan 31, 2025 | 268.13% |
| Oct 31, 2024 | 133.85% |
| Jul 31, 2024 | 149.22% |
| Apr 30, 2024 | 95.75% |
| Jan 31, 2024 | -3.46% |
| Oct 31, 2023 | -12,874.04% |
| Jul 31, 2023 | -705.32% |
| Apr 30, 2023 | -678.47% |
| Jan 31, 2023 | -428.85% |
| Oct 31, 2022 | -106.21% |
| Jul 31, 2022 | -83.81% |
| Apr 30, 2022 | 47.39% |
| Jan 31, 2022 | -17.25% |
| Oct 31, 2021 | 28,576.63% |
| Jul 31, 2021 | -343.53% |